Abstract
The non-myelotoxic antitumor drug thaliblastine (thalicarpine, NSC-68075, CAS-5373-42-21) has a novel chemical structure; it is a complex dimeric-type aporphine benzylisoquinoline alkaloid possessing antiproliferative and antitumor activities in experimental and clinical studies. In this study the effect of this drug on the cell cycle progression of ovarian tumor line O-342 and its cisplatin-resistant subline O-342/DDP was evaluated. As assessed by flow cytometric analysis, thaliblastine affected the cell cycle progression. In both lines, a comparable pattern of cell cycle arrest was found. Within the first 5 h of thaliblastine exposure, a G2/M block was observed; thereafter cell-cycle arrest in G1 became prominent, while S-phase-cells finished DNA replication.
This is a preview of subscription content, log in via an institution to check access.
References
Arnaudov I, Georgiev G, Petrov M, Serbesova M (1986) The effect of the Bulgarian antineoplastic agent thaliblastine in the treatment of patients with malignant lymphomas. In: Proceedings of the 1st International Symposium on Clinical Pharmacology, Sofia (abstract 13)
Broder L, Carter S (1971) Thalicarpine (NSC-68075) Clinical brochure. National Cancer Institute, Bethesda, MA
Chen G, Zeller WJ (1990) In vitro investigations of induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. J Cancer Res Clin Oncol 116: 443–447
Chen G, Hutter KJ, Bullerdiek J, Zeller WJ (1991) Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line. J Cancer Res Clin Oncol 117: 539–542
Chen G, Todorov DK, Zeller WJ (1992) Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin. Cancer Lett 62: 173–177
Chen G, Zeller WJ, Todorov DK (1993a) Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. Anticancer Res 13: 1269–1276
Chen G, Ramachandran C, Krishan A (1993b) Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein. Cancer Res 53: 2544–2547
Christov I, Krusteva E (1985) Thaliblastine — potential plant antitumor agent. In: Eckhardt S, Kerpel-Fronius S (eds) CMEA Chemotherapy Symposium, Akademiai Kiado, Budapest, pp 497–502
Christov I, Krusteva E, Ognyanova V, Tanev S (1986) Thaliblastine — the I–II phase clinical trials. In: Proceedings of the 14th International Cancer Congress, Budapest (abstract 452)
Creaven P, Cohen M, Selawry D, Teyada D, Broder L (1975) Phase I study of thalicarpine (NSC-68075), a plant alkaloid of novel structure. Cancer Chemother Rep 59: 1001–1006
Crissman HA, Tobey RA (1974) Cell cycle analysis in 20 minutes. Science 184: 1297–1298
Crissman HA, Stevenson AP, Kissane RJ, Tobey RA (1979) Techniques for quantitative staining of cellular DNA for flow cytometric analysis. In: Melamed MR, Mullaney PF, Mendelsohn ML, (eds) Flow cytometry and sorting. Wiley-Liss, New York, pp 243–261
Deliconstantinos G, Ramantanis G, Todorov DK (1983) Interaction of 99m Tc-labeled liposomes with Walker tumor cells. Gen Pharmacol 14: 407–411
Hutter KJ, Oldiges H (1980) Alterations of proliferating microorganisms by flow cytometric measurements after heavy metal intoxication. Ecotoxicol Environ Safety 4: 57–76
Ilarionova M, Maneva K, Todorov DK (1980) Pathomorphological studies on animals bearing experimental tumors treated with Thaliblastine. C R Acad Bulg Sci 33: 719–722
Kupchan S, Chakravarti K, Yokoyama N (1963) Thalicarpine, a new hypotensive alkaloid fromThalictrum dasycarpum. J Pharm Sci 52: 985–988
Kupchan S, Liepa A, Kameswaran V, Sempuku K (1973) Total synthesis of the tumor-inhibitory alkaloid thalicarpine. J Am Chem Soc 95: 2995–3000
Mircheva J, Stoychkov J (1976) Effect of thaliblastine on transplantable tumors in mice. Biomed Exp 25: 280–281
Mollov N, Dutschewska H, Panov P (1964) Über die Alkaloide von Thalictrum minus L. ssp. elatum bulgarischer Herkunft. C R Acad Bulg Sci 17: 709–712
Stöhr M, Futterman G (1991) Ein komplettes C-Programm für die 4-Parameter Flußzytometrie mit Personal Computer. In: Abstracts Heidelberger Zytometrie Symposium (Organizers: Goerttler K, Hutter K-J, Meuer S, Stöhr M), p 74
Todorov DK (1988) Thaliblastine. Drugs Future 13: 234–238
Todorov DK, Damyanova A (1975) Investigations into the acute toxicity of the antitumor alkaloid thaliblastine. C R Acad Bulg Sci 28: 709–711
Todorov DK, Zeller WJ (1992) Antiproliferative activity of the non-myelotoxic antitumor agent of plant origin, thaliblastine, on two human glioma cell lines. Cancer Res Clin Oncol 118: 83–86
Todorov DK, Pajeva IK, Zeller WJ, Chen G, Seydel JK (1994) Molecular mechanisms of overcoming MDR by the plant antitumor drug Thaliblastine at non-cytotoxic concentrations, achievable in the plasma of treated cancer patients. Anticancer Drugs 5 [Suppl1] 25
Tomita M, Furukava H, Lu S, Kupchan S (1965) The constitution of thalicarpine. Tetrahedron Lett 48: 4309–4316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seifert, F., Todorov, D.K., Hutter, KJ. et al. Cell cycle effects of thaliblastine. J Cancer Res Clin Oncol 122, 707–710 (1996). https://doi.org/10.1007/BF01209037
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01209037